




**Final Report**

Patient Name	MR. KIRAN BHAGWAN TAWARE	UHID	MGM240017131
Age / Gender	56 Yrs 2 Mth / MALE	Patient Case Type	IPD
Ref. Consultant	DR.PRASHANT ATHALE	Collection Date & Time	12-10-2024 13:34
Sample ID	MGM24152793	Result Entry Date & Time	12-10-2024 15:27
Ward/Bed No	SICU / SICU-010	Reporting Date & Time	14-10-2024 16:55:05
IP No.	MGMIP2406720	Receipt Number	MGMWPR240091810
			

**HAEMATOLOGY REPORT**

Test	Result	Unit	Biological Reference Interval
Sample Type: Citrate Plasma			
<b>PT - PROTHROMBIN TIME.</b>			
PT-Patients Time.. [ Colorimetry ]	15.40	Sec.	12.04-16.44
PT-Control Time.. [ Colorimetry ]	14.24	Sec.	
I.N.R. (International Normalised Ratio)..	1.10		**
I.S.I. Value of the prothrombin used..	1.17		
Prothrombin Index..	92.47	%	
Prothrombin Ratio..	1.08		

Medical Remarks: Kindly correlate clinically and with treatment history.

Test done on Fully Automated Coagulometer(Clottng)

**Interpretation:**

The INR is used only for patients on stable oral anticoagulant therapy. It makes no significant contribution to the diagnosis or treatment of patients whose PT is prolonged for other reasons.


\*\* Patient not on Anticoagulant Therapy : INR 0.8 – 1.2  
Recommended Therapeutic Range for Oral Anticoagulant Therapy:  
Prophylaxis of venous thrombosis (High risk surgery)INR 2.0- 3.0  
Treatment of Venous thrombosis : INR 2.0 – 3.0  
Treatment of pulmanory embolism : INR 2.0 – 3.0  
Valvular heart diseases : INR 2.0 – 3.0  
Mechanical prosthetic valves (High risk): INR 2.5 – 3.5  
Prevention of recurrent myocardial infaction : INR 2.5 – 3.5  
Reference Jaquas Wallach 7<sup>th</sup> Edition Page No. 11

\*Biological reference interval changes with every lot change.

**\*\*\*End of the Report\*\*\***



TECH. ANITA EBENEZER

  
PATHOLOGIST  
DR. JOYCE THOMAS  
MBBS, MD PATHOLOGY

